On Wednesday, U.S. Stocks tumbled after the Fed gave no indication that it is indecisive on climbing interest rates for a while in the second half of 2015. The U.S. central bank was cheerful about the economy, while the policy makers said again that they think inflation will fall back to the 2% target after being pressurized by short-term factors.
Headline Biotech Sector:
Abiomed Inc. (NASDAQ:ABMD), surged 29.28% after the medical device maker posted earnings that blew out Wall Street estimates.
Health Care SPDR (XLV), iShares Dow Jones US Healthcare (IYH) and Vanguard Health Care ETF (VHT) were higher. In the meantime, Biotech ETF iShares NASDAQ Biotechnology Index (IBB) was dipped 0.61%.
The main focus of this article is to share financials along with latest news and profiles, of such biotech sector companies, which moved up during their Wednesday trading session.
Exelixis, Inc (NASDAQ:EXEL), gained +14.61% to $2.04, during its last trade, soon after a biopharmaceutical company, declared that it has extended and restructured its contract with Swedish Orphan Biovitrum AB (Sobi) to support the distribution and commercialization of COMETRIQ® (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia, and Turkey. The contract, which was established in February 2013 and due to expire on December 31, 2015, will now extend to December 31, 2019.
Exelixis, Inc (NASDAQ:EXEL) a biopharmaceutical organization, develops small molecule therapies for the treatment of cancer in the United States. The organization focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Ariad Pharmaceuticals, Inc (NASDAQ:ARIA), increased +1.39% to close at $6.55, during its last trading session, as an oncology company, declared the selection of Thomas J. DesRosier, Esq. to the position of executive vice president, chief legal and administration officer, and secretary. Mr. DesRosier will be accountable for global legal operations, information technology and other administrative functions. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D.
Ariad Pharmaceuticals, Inc (NASDAQ:ARIA), headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines.
XOMA Corp (NASDAQ:XOMA), inclined 0.81% and closed at $3.72, on a traded volume of $2,200,459 shares, in comparison to $2,839,080 shares of average trading volume. The company has a total market capitalization of $399.51M. The company has 52-week range of $3.25 - $9.57.
XOMA Corp (NASDAQ:XOMA), discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Its proprietary products comprise gevokizumab, a humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III studies for non-infectious uveitis, Behçet’s uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, cardiovascular disease, Schnitzler syndrome, and other diseases, in addition to diseases under the neutrophilic dermatoses designation; and various proof-of-concept studies, counting polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP), declined -0.02% to close at $45.91, during its last trade, following the news that a biopharmaceutical company, declared that the U.S. Food and Drug Administration (FDA) has accepted Natpara® as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH. Natpara, a bioengineered replica of human PTH, is predictable to be accessible in the second quarter of 2015.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases. The company’s current therapeutic areas of focus are gastrointestinal disease and endocrine disorders.
